Lattanzi S, Brigo F, Trinka E, et al. Adjunctive Cannabidiol in Patients with Dravet Syndrome: A Systematic Review and Meta-Analysis of Efficacy and Safety. CNS Drugs. 2020 Mar;34(3):229-241.
Szaflarski JP, Bebin EM, Comi AM, et al. Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: Expanded access program results. Epilepsia. 2018 Aug;59(8):1540-1548.
Devinsky O, Cross JH, Wright S. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. N Engl J Med. 2017 May 25;376(21):2011-2020..
Mueller A, Fixen DR. Use of Cannabis for Agitation in Patients With Dementia. Sr Care Pharm. 2020 Jul 1;35(7):312-317.
van den Elsen GA, Tobben L, Ahmed AI, et al. Effects of tetrahydrocannabinol on balance and gait in patients with dementia: A randomised controlled crossover trial. J Psychopharmacol. 2017 Feb;31(2):184-191.
Herrmann N, Ruthirakuhan M, Gallagher D, et al. Randomized Placebo-Controlled Trial of Nabilone for Agitation in Alzheimer’s Disease. Am J Geriatr Psychiatry. 2019 Nov;27(11):1161-1173.
Barchel D, Stolar O, De-Haan T, et al. Oral Cannabidiol Use in Children With Autism Spectrum Disorder to Treat Related Symptoms and Co-morbidities. Front Pharmacol. 2019 Jan 9;9:1521
Fleury-Teixeira P, Caixeta FV, Ramires da Silva LC, et al. Effects of CBD-Enriched Cannabis sativa Extract on Autism Spectrum Disorder Symptoms: An Observational Study of 18 Participants Undergoing Compassionate Use. Front Neurol. 2019 Oct 31;10:1145.
Aran A, Cassuto H, Lubotzky A, et al. Brief Report: Cannabidiol-Rich Cannabis in Children with Autism Spectrum Disorder and Severe Behavioral Problems-A Retrospective Feasibility Study. J Autism Dev Disord. 2019 Mar;49(3):1284-1288.
Bar-Lev Schleider L, Mechoulam R, Saban N, et al. Real life Experience of Medical Cannabis Treatment in Autism: Analysis of Safety and Efficacy. Sci Rep. 2019 Jan 17;9(1):200.
